Rajeev Suri
Known title: DirectorCIK: 0001738349
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
ViaSat sees high call options volume amid sector news. ViaSat is experiencing significant call options volume, suggesting heightened market interest in potential price movement. This activity occurs alongside broader news regarding SpaceX and satellite connectivity, which may be influencing sentiment toward the company. The stock remains within its 52-week range, with technical indicators showing a neutral RSI and confirmed support levels.
Transaction History
| SYK | ▲ Buy | Grant | 762 | $0 | 5/6/2026 | View on chart |
| SYK | ▲ Buy | Grant | 560 | $0 | 5/8/2025 | View on chart |
| VSAT | ▲ Buy | Option Exercise | 1,600 | $0 | 9/7/2024 | View on chart |
| VSAT | ▲ Buy | Option Exercise | 1,000 | $0 | 5/30/2024 | View on chart |
| SYK | ▲ Buy | Grant | 653 | $0 | 5/9/2024 | View on chart |
| VSAT | ▲ Buy | Grant | 258,051 | — | 5/30/2023 | View on chart |
| SYK | ▲ Buy | Grant | 705 | $0 | 5/10/2023 | View on chart |
| SYK | ▲ Buy | Option Exercise | 841 | $0 | 5/4/2023 | View on chart |
| SYK | ▲ Buy | Option Exercise | 693 | $0 | 5/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3
Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3. Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.